VRTX - Vertex Pharmaceuticals Inc Stock Price Quote - NASDAQ (2023)


Show Full Chart

After hours: 349.01 0.62| 0.18%

| Currency in USD

  • Last Close 351.91
  • Sector Healthcare
  • Industry Biotechnology
  • Investment Style Large Growth
  • Day Range 348.67352.90
  • Year Range 271.61367.00
  • Market Cap 90.0503 Bil
  • Volume / Avg 895,490.0/1.3 Mil
  • Price / Sales 9.93
  • Price / Book 6.28
  • Forward Div Yield
  • Trailing Div Yield

Morningstar‘s Stock Analysis VRTX


Currency in

Is it the right time to buy or sell?

Find out with Morningstar Investor

Is it the right time to buy or sell?

Find out with Morningstar Investor

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Narrow-Moat Vertex Benefits From Strong Intangible Assets; Positive Outlook for the Firm

Rachel Elfman Equity Analyst

Business Strategy and Outlook

|Rachel Elfman |

Vertex Pharmaceuticals, which was once known for discovering Incivek, a blockbuster hepatitis C drug is now overshadowed by a robust cystic fibrosis (CF) franchise. Vertex's approved cystic fibrosis drugs are Kalydeco, Orkambi, Symdeko, and Trikafta, which will make Vertex eligible to treat about 90% of the CF population, assuming international and pediatric approvals. We expect Vertex to maintain its dominant position in CF, given the strong efficacy of its therapies, lengthy patents, and lack of competition, while developing pipeline candidates in other rare indications to spur growth.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics VRTX


Company Profile VRTX

Business Description

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.


50 Northern Avenue
Boston, MA, 02210

Sector Healthcare

Industry Biotechnology

Employees 4,800

Related Articles VRTX

Stock Analyst Update Vertex Earnings: Robust Demand for Cystic Fibrosis Drugs; Diverse Pipeline Makes Progress Rachel Elfman
Stock Strategist 10 Undervalued, High-Quality Stocks With Competitive Advantages Wide-moat names including Adobe and Microsoft have strong balance sheets and discounted stock prices. Lauren Solberg
Our Picks 6 Undervalued Biotech Stocks for 2023 These stocks from the Morningstar US Biotechnology Index look cheap. Margaret Guidici
Market Update How a Top Fidelity Growth Fund Is Navigating This Market Looking for 'growth quality' has helped cushion the blow in a big down year. Tom Lauricella
Stock Strategist Industry Reports Inoculated Against Uncertainty Big Biopharma can stand up against stiff macro headwinds. Laura Lallos
Sustainability Matters How Drug Pricing Can Increase ESG Risks for Pharmaceutical Stocks New Morningstar research highlights Big Pharma’s exposure to ESG risk. Two winners: BioMarin and Sanofi. Karen Andersen
Market Update Growth-Stock Funds That Have Stayed Near the Top These funds have managed to stay in the top third of the large-growth category. Katherine Lynch
Our Picks 40 Defensive Stocks on Sale These quality names are trading at 4- and 5-star levels. Susan Dziubinski

Related News VRTX

Vertex to Announce Second Quarter 2023 Financial Results on August 1

Provided by Business Wire

Weight-loss drugs in development aim to replace injections with pills

Provided by Dow Jones

Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes (T1D) Cell Therapies

Provided by Business Wire

Vertex Presents Positive VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the American Diabetes Association 83rd Scientific Sessions

Provided by Business Wire

Vertex Presents Data Demonstrating Significant Benefits of Long-Term Treatment With CFTR Modulators at the European Cystic Fibrosis Conference

Provided by Business Wire

Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress

Provided by Business Wire

FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Provided by Business Wire

Vertex to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference on June 13

Provided by Business Wire

Competitors & PeersVRTX

Morningstar analysts hand-select direct competitors or comparable companies toprovide context on the strength and durability of VRTX’scompetitive advantage.

Vertex Pharmaceuticals Inc


Alnylam Pharmaceuticals Inc


Biomarin Pharmaceutical Inc


Seagen Inc Ordinary Shares








Market Cap

90.05 Bil24.27 Bil16.25 Bil35.92 Bil








* Trading data in this section is delayed by at least 15 minutes.

FAQs for Vertex Pharmaceuticals Inc Stock

Does VRTX pay dividends? If so, how much?

No. VRTX does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks,to compare the relationship between a stock’s price and how it rewards stockholders through dividends.The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

How big is Vertex Pharmaceuticals Inc?

VRTX’s market cap is 90.05 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares.It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for thelargest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

What is Vertex Pharmaceuticals Inc’s stock style?

VRTX’s stock style is Large Growth.
Style is an investment factor that has a meaningful impact on investment risk and returns.Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors.They rarely distribute dividends to shareholders, opting for reinvestment in their businesses.More value-oriented stocks tend to represent financial services, utilities, and energy stocks.These are established companies that reliably pay dividends.

Learn more about style.

How expensive is VRTX?

VRTX’s price/sales is 9.93.
Price/sales represents the amount an investor is willing to pay for a dollar generated froma particular company’s sales or revenues.

VRTX’s price/forward earnings is 28.04.
Forward P/E gives some indication of how cheap or expensive a stock is compared with consensus earnings estimates.The lower the Forward P/E, the cheaper the stock.

VRTX’s price/book is 6.28.
Price/book ratio can tell investors approximately how much they’re paying for a company’s assets,based on historical, rather than current, valuations. Historical valuations generally do not reflecta company’s current market value. Value investors frequently look for companies that have low price/book ratios.

SeeVRTX’s valuation ratioscompared to the Market Index.

How has VRTX performed historically compared to the market?

VRTX’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

CompareVRTX’s historical performanceagainst its industry peers and the overall market.


What is the analyst price target for VRTX? ›

Average RecommendationOverweight
Average Target Price381.54
Number Of Ratings32
FY Report Date12/2023
Last Quarter's Earnings3.05
6 more rows

Is VRTX a buy right now? ›

Out of 18 analysts, 8 (44.44%) are recommending VRTX as a Strong Buy, 5 (27.78%) are recommending VRTX as a Buy, 5 (27.78%) are recommending VRTX as a Hold, 0 (0%) are recommending VRTX as a Sell, and 0 (0%) are recommending VRTX as a Strong Sell.

What is the stock price forecast for VRTX 2025? ›

For Vertex Pharmaceuticalsrpor Stock (VRTX) price forecast for 2025, a forecast is offered for each month of 2025 with average VRTX price forecast of $527.50, a high forecast of $549.90, and a low forecast of $391.66.

How many outstanding shares does VRTX have? ›

Key Data
  • Open $2.9400.
  • 52 Week Range 1.6100 - 5.7800.
  • Market Cap $72.79M.
  • Shares Outstanding 25.01M.
  • Public Float 12.34M.
  • Beta 0.84.
  • Rev. per Employee N/A.
  • P/E Ratio N/A.

What is the yield on VRTX stock? ›

Historical dividend payout and yield for Vertex Pharmaceuticals (VRTX) since 1971. The current TTM dividend payout for Vertex Pharmaceuticals (VRTX) as of July 12, 2023 is $0.00. The current dividend yield for Vertex Pharmaceuticals as of July 12, 2023 is 0.00%.

How often are analyst price targets correct? ›

Despite the best efforts of analysts, a price target is a guess with the variance in analyst projections linked to their estimates of future performance. Studies have found that, historically, the overall accuracy rate is around 30% for price targets with 12-18 month horizons.

Will Vertex Energy stock recover? ›

Average Price Target

Based on 3 Wall Street analysts offering 12 month price targets for Vertex Energy in the last 3 months. The average price target is $11.00 with a high forecast of $12.00 and a low forecast of $10.00. The average price target represents a 75.16% change from the last price of $6.28.

Does VRTX have a dividend? ›

Vertex Pharmaceuticals (VRTX) does not pay a dividend.

What is the forecast for V stock? ›

Visa Inc (NYSE:V)

The 34 analysts offering 12-month price forecasts for Visa Inc have a median target of 277.50, with a high estimate of 336.00 and a low estimate of 220.00. The median estimate represents a +17.02% increase from the last price of 237.13.

Will Vertex Pharmaceuticals stock go up? ›

Average Price Target

Based on 23 Wall Street analysts offering 12 month price targets for Vertex Pharmaceuticals in the last 3 months. The average price target is $375.05 with a high forecast of $456.00 and a low forecast of $325.00. The average price target represents a 3.47% change from the last price of $362.46.

Is Vertex Inc a good stock to buy? ›

Stock Price Forecast

The 10 analysts offering 12-month price forecasts for Vertex Inc have a median target of 23.50, with a high estimate of 28.00 and a low estimate of 20.00. The median estimate represents a +23.04% increase from the last price of 19.10.

What is the 5 year forecast for VRTX? ›

quote is equal to 1.210 USD at 2023-07-23. Based on our forecasts, a long-term increase is expected, the "VRTX" stock price prognosis for 2028-07-14 is 156.623 USD. With a 5-year investment, the revenue is expected to be around +12844.02%. Your current $100 investment may be up to $12944.02 in 2028.

Who owns VRTX? ›

Institutional investors hold a majority ownership of VRTX through the 94.63% of the outstanding shares that they control. This interest is also higher than at almost any other company in the Biotechnology industry.

What was vertex ipo price? ›

Late Tuesday, Vertex raised $401 million after selling 21.15 million shares at $19. That's above its $14 to $16 price range. Lead underwriters on the deal include Goldman Sachs and Morgan Stanley. Shares of Vertex (Ticker: VERX) added $5.50, or 29%, to $24.50 in afternoon trading Wednesday on the Nasdaq.

What does VRTX stand for? ›

VRTX may refer to: Versatile Real-Time Executive, a real-time operating system. Vertex Pharmaceuticals (Nasdaq stock symbol) PowerEdge VRTX, a computer hardware product line from Dell.

What is now analyst price target? ›

ServiceNow Inc (NYSE:NOW)

The 34 analysts offering 12-month price forecasts for ServiceNow Inc have a median target of 549.50, with a high estimate of 665.00 and a low estimate of 410.00. The median estimate represents a -5.31% decrease from the last price of 580.34.

What is the analyst price target for Vlo? ›

Valero Energy Corp (NYSE:VLO)

The 19 analysts offering 12-month price forecasts for Valero Energy Corp have a median target of 142.00, with a high estimate of 171.00 and a low estimate of 113.00. The median estimate represents a +15.45% increase from the last price of 123.00.

Top Articles
Latest Posts
Article information

Author: Amb. Frankie Simonis

Last Updated: 14/12/2023

Views: 6517

Rating: 4.6 / 5 (76 voted)

Reviews: 83% of readers found this page helpful

Author information

Name: Amb. Frankie Simonis

Birthday: 1998-02-19

Address: 64841 Delmar Isle, North Wiley, OR 74073

Phone: +17844167847676

Job: Forward IT Agent

Hobby: LARPing, Kitesurfing, Sewing, Digital arts, Sand art, Gardening, Dance

Introduction: My name is Amb. Frankie Simonis, I am a hilarious, enchanting, energetic, cooperative, innocent, cute, joyous person who loves writing and wants to share my knowledge and understanding with you.